3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Sarcoma
2
Other solid neoplasm
2
Gastrointestinal
2
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Renal Cell
4
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
Nivolumab
3
sargramostim
2
pembrolizumab
2
atezolizumab
2
Platinum
2
Cyclophosphamide
2
tazemetostat
1
regorafenib
1
enzalutamide
1
entinostat
1
durvalumab
1
cemiplimab
1
cabozantinib
1
avelumab
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Pemetrexed
1
Paclitaxel
1
Microarray Analysis
1
Levoleucovorin
1
Leucovorin
1
Ipilimumab
1
Interleukin-2
1
Interferon-gamma
1
Interferon-alpha
1
In Situ Hybridization, Fluorescence
1
Immunoenzyme Techniques
1
Immune Checkpoint Inhibitors
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gene Expression Profiling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
regorafenib
×
Genitourinary
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled